News & Events

Filter By:

Subscribe to our PRs

Subscribed

Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures

Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager

Inspira™ Technologies Reports Full Year 2023 Financial Results

Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone

Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements

Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

Inspira™ Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device

Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices

Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity

Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering

Inspira™ Announces $3.88 Million Registered Direct Offering

Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024

Inspira™ Technologies to Participate in J.P. Morgan Healthcare Conference

In Preparation for FDA Clearance and Device Deployment, Inspira™ has Appointed Dr. Dan Gorfil, to Medical Advisory Board

Inspira™ Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

Inspira™ Technologies Reports Third Quarter 2023 Financial Results

Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology

Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device

Inspira™ Terminates ATM Program and Provides an Update

Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP

Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards Commercialization

Inspira™ Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA™ ART Respiratory Medical Devices

Inspira™ Technologies Reports Second Quarter 2023 Financial Results

INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.

Inspira™ Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval

Inspira™ Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc.

Inspira™ Technologies Unveils Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Inspira™ Technologies Reports First Quarter 2023 Financial Results

Inspira™ Technologies will Reveal the New ALICE™ Device at the World’s Largest Extracorporeal Life Support Conference

Inspira™ Technologies is Developing the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results

Inspira™ Technologies Announces First in Human of HYLA™ Blood Sensor in Clinical Study

VP operations presents the start of ALICE™ Device manufacturing

Inspira™ Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA™ Blood Sensor

Inspira™ Technologies Granted Patent by U.S. Patent Office for the INSPIRA™ ART System’s Convertible Dual Lumen Cannula Device and Method of Use

Diamond Equity Research Initiates Coverage on Inspira Technologies Ltd. (NASDAQ: IINN)

Creating a Paradigm Shift in Respiratory Care: Early Respiratory Support Reducing the Need for Invasive Mechanical Ventilation / by HAARETZ

Inspira™ Technologies Signs Strategic OEM Agreement with Terumo Cardiovascular

VP clinical affairs video presents the upcoming clinical trial in Sheba hospital

Inspira™ Technologies Begins Manufacturing of the ALICE™ CPB Device, Ahead of Planned 2023 FDA Submission

Inspira™ Technologies Signs Agreement to Conduct Clinical Study of HYLA™ Blood Sensor

Inspira™ Technologies Reports Third Quarter 2022 Financial Results

Inspira™ Technologies Signs a Strategic Agreement in Europe to potentially provide $26.1 Million for Deployment of 1,364 HYLA™ Blood Sensors

Inspira™ Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRA™ ART System

Inspira™ Technologies Performed HYLA™ Blood Sensor In-Vivo Study, in Preparation of Planned Human Studies

Inspira™ Technologies to Present at the H.C. Wainwright 24th Annual Global Investor Conference

Inspira™ Technologies Reports Second Quarter 2022 Financial Results

Inspira™ Technologies Signs Strategic Agreement in U.S. to potentially provide $59 million for Inspira for deployment of 3,889 HYLA™ Blood Sensors

Inspira™ Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients – Potentially Targets $2.5 Billion ABG Market

Inspira™ Technologies Strategically Plans to Actualize Hundreds of Millions in Conditional Distribution Agreements / by Benzinga

Inspira™ Technologies Announces 2022 first Quarter Financial Results

Inspira™ Technologies to Participate in Upcoming Events in May

The Disruptive MedTech Company Aiming to Minimise Patients’ Need for Invasive Mechanical Ventilation Intervention / by Campden FB

Inspira Technologies Announces Deployment Agreement in the Israeli Market to Target $15M

Inspira Technologies Releases Q4 & FY2021 Financial Results

Inspira Technologies Releases Q4 & FY2021 Financial Results – CEO Update

Inspira Technologies will present its “artificial lungs” technology in front of family offices from all over the world

Inspira Technologies, The Company That Aims To Change 50 Years Of Therapeutic Paradigm In Patients With Respiratory Failure

Inspira Technologies Is Awarded the 2021 Frost & Sullivan Technology Innovation Leadership Award

Inspira Technologies – Awarded with the 2021 Frost & Sullivan Best Practices Technology Innovation Leadership Award

The Respiratory Care Market – Factors Driving the Market and Opportunities for Inspira Technologies’ Products

Inspira Technologies to Present at the Aegis Capital Corp. Virtual Conference

Inspira Technologies Appointed an Expert in the Field of Artificial Lung as the New Chief Technology Officer (CTO)

Inspira Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period, Subject to Regulatory Approvals

Inspira Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period

Inspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system

Professor Daniel Brodie, Director of Critical Care from New-York Columbia – Presbyterian Hospital, Has Joined Inspira Technologies’ Advisory Board

Inspira Technologies Signs Strategic Agreement with Innovimed

Inspira Technologies Files a PCT Patent Application for its Flagship ART Device and Proprietary Method of Use

Prof Eddy Fan has joined Inspira’s Scientific Advisory Board

Third Quarter Financial Reports Results

Inspira Technologies Announces 2021 Third Quarter Financial Results; In October 2021, Company increases cash balance by $9.4 Million due to investors Exercising Warrants

Dr. Stephane Ledot, an Expert in Critical Care and Anesthesia, Has Joined Inspira Technologies’ Scientific Advisory Board

Joe Hayon Presents at the H.C. Wainright 7th Annual Israel Conference

Inspira to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

Inspira Technologies Files a PCT Patent Application for its Novel Dual Lumen Cannula Used for Blood Oxygenation

Has COVID changed the game and what are the opportunities for Inspira’s ART device? Dr. Kassif, The Chairman of the Israeli ECMO Society

Inspira Technologies Signs a Strategic Agreement With Waas Group

“Millions May Soon Breath Better” – Inspira at Forbes

Inspira Technologies to Present In-Person at the HLTH Conference in Boston

Inspira Technologies to Host COVID-19 Virtual Conference on October 6

Inspira Technologies’ “Artificial Lung” to Acquire a Digital Edge: The Company Contracted GlobalLogic, a Hitachi Group Company, for Advanced Digital Product Engineering Services

Inspira Technologies’ “Artificial Lung” To Acquire A Digital Edge: The Company Contracted GlobalLogic, A Hitachi Group Company, For Advanced Digital Product Engineering Services

Inspira Technologies Files a Patent Application for a Supportive Device to be Utilized with the ART Device

Listen To Joe Hayon, Inspira-Technologies’ President, CFO & Co-Founder, Sharing Inspira’s Sharing The Company’s Go-To-Market Strategy

Inspira Technologies to Participate in Upcoming Conferences in September

Inspira Technologies Announces First Half 2021 Financial Results and Provides Business Update

Inspira Technologies Expands Board of Directors to Accelerate Company’s Go-to-Market Efforts

Low Flow Extracorporeal Oxygenation Approach Is The Future Of Acute Respiratory Care

An Interview With Dagi Ben-Noon, CEO At Inspira Technologies

Top 115 Medical And Healthcare Startups In Israel

EXCLUSIVE: Inspira Aims To Replace Mechanical Ventilation With Augmented Respiratory Technology

Inspira Expands Medical Advisory Board as Part of Future Expansion into North American Market

10+ Best Healthcare Startups: Inspiration And Brave Findings Nearby

Inspira Technologies and Ben-Gurion University Have Developed a Platform Designed to Prevent Blood Clotting in Inspira’s ART System

Inspira Technologies Reached Important Milestone as It Completed a Pump Bench Study

Inspira Technologies OXY B.H.N. Ltd Announces Closing of Initial Public Offering

Inspira Technologies OXY B.H.N. Ltd Announces Pricing of Initial Public Offering

The Future Of Respiratory By Inspira Technologies: Breathing Without Lungs

INSPIRA-Technologies Announces New Medical Advisory Board Member – Dr. Avraham Abutbul – Specialist in Internal Medicine, General Intensive Care Medicine and Pulmonary Medicine

Inspira’s Proprietary Augmented Respiration Technology (ART)

Q&A: An Intelligent Oxygenation System That Could Eliminate Need For Ventilators

This IPO Stock Resembles Nanox, Is Inspira IINN Stock A Buy

Breakthrough Oxygenation | Professor Benad Goldwasser

Hillel’s Tech Corner: Inspira Makes Breathing Easy

Inspira Technologies

Inspira Technologies Appoints Benad Goldwasser As Chairman Of The Board

Inspira Technologies and Sheba Medical Center Collaborate on Breakthrough Respiration Treatment

Sheba And Inspira Technologies Implement Respiratory Treatment For Covid-19 Patients

Inspira Technologies Reveals the AXT – An Intelligent System that Directly Oxygenates Blood for Respiratory Care

Inspira Technologies Files U.S. Patent Application for its Innovative Respiratory Support Technology; Engages Leading U.S. Investment Bank for NASDAQ Listing

Get in Touch!

Ha-Tidhar St 2, Ra'anana, Israel

Join Our Newsletter!

Sign up and be the first to get notified on new updates of Inspira Technologies

Copyright © 2018-2022 Inspira-Technologies OXY B.H.N. LTD., All rights reserved